Detalhe da pesquisa
1.
Outcomes of younger patients with mantle-cell lymphoma experiencing late relapse (>24 months): the LATE-POD study.
Blood
; 2024 05 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-38754055
2.
Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network.
Lancet
; 403(10441): 2293-2306, 2024 May 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38705160
3.
Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The SCHOLAR-2 retrospective chart review study.
Br J Haematol
; 202(4): 749-759, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-36257914
4.
RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma.
Ann Hematol
; 102(7): 1773-1787, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-37171597
5.
The CAR-HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL.
Am J Hematol
; 98(11): 1699-1710, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37584447
6.
A phase II trial to evaluate the combination of pixantrone and obinutuzumab for patients with relapsed aggressive lymphoma: Final results of the prospective, multicentre GOAL trial.
Br J Haematol
; 198(3): 482-491, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35362552
7.
90-yttrium-ibritumomab tiuxetan as first-line treatment for follicular lymphoma: updated efficacy and safety results at an extended median follow-up of 9.6 years.
Ann Hematol
; 101(4): 781-788, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-35150296
8.
Struggling with extensive informed consent procedures for cancer trials-is there even a benefit for the patients?
Support Care Cancer
; 30(8): 6593-6602, 2022 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-35486229
9.
Cure rate in the elderly patients with diffuse large B cell lymphoma deteriorates after the age of 80-results from a single-center survey.
Ann Hematol
; 100(4): 1013-1021, 2021 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-33634349
10.
Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma.
Blood
; 127(11): 1410-6, 2016 Mar 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-26755709
11.
Correction to: REMIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (polaBR), CART therapies, and lenalidomide/rituximab (R2) based on realworld data in patients with relapsed/refractory diffuse large Bcell lymphoma.
Ann Hematol
; 102(9): 2643-2644, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37432417
12.
Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies.
Br J Haematol
; 179(3): 430-438, 2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28832957
13.
Phase II study of bortezomib, cyclophosphamide and dexamethasone as induction therapy in multiple myeloma: DSMM XI trial.
Br J Haematol
; 179(4): 586-597, 2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28961309
14.
Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study.
Lancet
; 387(10020): 770-8, 2016 Feb 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-26673811
15.
Hemodynamic Determinants of the Biologic Variation of N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Stable Systolic Chronic Heart Failure.
J Card Fail
; 23(12): 835-842, 2017 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-28757153
16.
Patterns of failure of diffuse large Bcell lymphoma patients after involved-site radiotherapy.
Strahlenther Onkol
; 193(12): 1014-1023, 2017 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-28748453
17.
Clinical activity of abemaciclib in patients with relapsed or refractory mantle cell lymphoma - a phase II study.
Haematologica
; 106(3): 859-862, 2021 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32381571
18.
Rituximab combined with DexaBEAM followed by high dose therapy as salvage therapy in patients with relapsed or refractory B-cell lymphoma: mature results of a phase II multicentre study.
Br J Haematol
; 168(6): 824-34, 2015 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-25546611
19.
Ofatumumab retreatment and maintenance in fludarabine-refractory chronic lymphocytic leukaemia patients.
Br J Haematol
; 170(1): 40-9, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-25825041
20.
Malignant lymphomas in the head and neck region--a retrospective, single-center study over 41 years.
Int J Med Sci
; 12(2): 141-5, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25589890